title: First US experience following FDA approval of the ABBOTT vascular bioresorbable vascular scaffold for the treatment of coronary artery disease.
abstract: Drug eluting stents are considered the "gold standard" for the percutaneous treatment of coronary artery disease. Recent publications have suggested that a reasonable alternative, in well selected cases, may be the ABSORBTM bioresorbable vascular scaffold (BVS) stent. © 2016 Wiley Periodicals, Inc.
authors.affiliation: HonorHealth and the Scottsdale-Lincoln Health Network, Scottsdale, Arizona.
authors.forename: David G
authors.initials: DG
authors.lastname: Rizik
authors.affiliation: HonorHealth, Scottsdale, Arizona.
authors.forename: Maulik G
authors.initials: MG
authors.lastname: Shah
authors.affiliation: HonorHealth, Scottsdale, Arizona.
authors.forename: Robert F
authors.initials: RF
authors.lastname: Burke
mesh_terms: D020341:Absorbable Implants; D000368:Aged; D000369:Aged, 80 and over; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000601:surgery*; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000601:surgery*; D017277:Drug Approval; D054855:Drug-Eluting Stents; D006801:Humans; D008297:Male; D008875:Middle Aged; D011474:Prosthesis Design; D054457:Tissue Scaffolds; D014481:United States; D014486:United States Food and Drug Administration
keywords: bioabsorbable devices/polymers; coronary artery disease; stent restenosis